Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to…
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis…
Read More...
Read More...